Overview

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

Status:
Not yet recruiting
Trial end date:
2023-11-03
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Incyte Corporation